Trials / Recruiting
RecruitingNCT05864196
Two Fraction Prostate SBRT With DIL SIB
A Phase I/Ib, Single Arm Study of Two Fraction Stereotactic Body Radiation Therapy (SBRT) With Dominant Lesion Simultaneous Integrated Boost (SIB) for the Treatment of Low to Intermediate Risk Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer. The primary purpose of this study is to determine the feasibility and safety of two fraction SBRT in patients with localized prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Two-Fraction Stereotactic Body Radiation Therapy (SBRT) | Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer. |
Timeline
- Start date
- 2023-07-17
- Primary completion
- 2028-06-01
- Completion
- 2030-06-01
- First posted
- 2023-05-18
- Last updated
- 2026-01-29
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05864196. Inclusion in this directory is not an endorsement.